Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. The company’s lead drug candidate, SLV213, is an orally available small molecule novel antiviral therapy with activity against a broad range of viruses that threaten global health, including SARS-CoV-2, the virus causing COVID-19. In addition, SLV213 has activity against Ebola and Nipah viruses and has completed preclinical development as a potential therapy against Chagas disease. Selva is headquartered in San Diego.
Location: United States, California, San Diego
Employees: 1-10
Total raised: $3M
Investors 1
| Date | Name | Website |
| - | Flying Poi... | flyingpoin... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.07.2020 | Series A | $3M | - |
Mentions in press and media 1
| Date | Title | Description |
| 21.07.2020 | Selva Therapeutics Raises $3M in Series A Financing | Selva Therapeutics, Inc., a San Diego, CA-based biotechnology company, raised $3m in Series A financing. The company intends to use the funds to advance SLV213 into clinical trials as an oral drug candidate for the treatment of COVID-19, th... |